00

Huapont Life Sciences Co LtdSHE 002004 Stock Report

Last reporting period 30 Sep, 2023

Updated 19 Sep, 2024

Last price

Market cap $B

1.134

Small

Exchange

XSHE - Shenzhen Stock Exchange

002004.SZ Stock Analysis

00

Avoid

Based on Eyestock quantitative analysis, 002004.SZ`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

28/100

Low score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-49.8 %

Greatly overvalued

Market cap $B

1.134

Dividend yield

9.50 %

Shares outstanding

1 931.63 B

Huapont Life Sciences Co., Ltd. engages in the manufacture of chemical raw materials. The company is headquartered in Chongqing, Chongqing and currently employs 12,206 full-time employees. The company went IPO on 2004-06-25. The firm operates through three segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sales of skin pharmaceuticals, antituberculous pharmaceuticals and other manufactured products. Its products include fleroxacin and ambroxol hydrochloride for injection, and lecithin-bound iodine capsules, among others. The Pesticide Chemical segment is engaged in the production and sales of pesticides and other fine chemicals, including herbicides, bactericides and insecticides, among others. The Bulk Drug segment is engaged in the research and development and manufacture of bulk drugs and medical intermediates. The firm is also engaged in the provision of travel services, the sales of tea and the provision of technical services, among others.

View Section: Eyestock Rating